{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:53:07Z","timestamp":1761630787809,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T00:00:00Z","timestamp":1494979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Smoking remains one of the major causes of morbidity and mortality worldwide. One approach to assisting smoking cessation is via anti-nicotine vaccines, composed of nicotine-like haptens conjugated to a carrier protein plus adjuvant(s). We have previously shown that the carrier, hapten, linker, hapten load, degree of conjugate aggregation, and presence of adducts can each influence the function (nicotine-binding capacity) of the antibody (Ab) induced. Herein, we extend those findings and show that tertiary structure is also critical to the induction of functional immune responses and that this can be influenced by conjugation conditions. We evaluated immunogenicity in mice using six lots of NIC7-CRM, a conjugate of 5-aminoethoxy-nicotine (Hapten 7), and a single point (glycine 52 to glutamic acid) mutant nontoxic form of diphtheria toxin, cross-reactive material 197 (CRM197), which were synthesized under different reaction conditions resulting in conjugates with equivalent molecular characteristics (hapten load, aggregates, adducts), but a different tertiary structure. When tested in mice, better functional responses (reduced nicotine in the brain of immunized animals relative to non-immunized controls) were obtained with conjugates with a more closed structure than those with an open conformation. These studies highlight the need for a better understanding of the physicochemical properties of small molecule conjugate vaccines.<\/jats:p>","DOI":"10.3390\/vaccines5020011","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T11:13:17Z","timestamp":1495019597000},"page":"11","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Effect of Physicochemical Modification on the Function of Antibodies Induced by Anti-Nicotine Vaccine in Mice"],"prefix":"10.3390","volume":"5","author":[{"given":"Jennifer","family":"Thorn","sequence":"first","affiliation":[{"name":"Pfizer Biotherapeutics Pharmaceutical Sciences, Chesterfield, MO 63017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keshab","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Pfizer Biotherapeutics Pharmaceutical Sciences, Chesterfield, MO 63017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Crutcher","sequence":"additional","affiliation":[{"name":"Pfizer Biotherapeutics Pharmaceutical Sciences, Chesterfield, MO 63017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Sperry","sequence":"additional","affiliation":[{"name":"Pfizer Biotherapeutics Pharmaceutical Sciences, Chesterfield, MO 63017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Isele","sequence":"additional","affiliation":[{"name":"Pfizer Biotherapeutics Pharmaceutical Sciences, Chesterfield, MO 63017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kelly","sequence":"additional","affiliation":[{"name":"Pfizer Biotherapeutics Pharmaceutical Sciences, Chesterfield, MO 63017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libbey","family":"Yates","sequence":"additional","affiliation":[{"name":"Pfizer Biotherapeutics Pharmaceutical Sciences, Chesterfield, MO 63017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Zobel","sequence":"additional","affiliation":[{"name":"Pfizer Biotherapeutics Pharmaceutical Sciences, Chesterfield, MO 63017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Immunotherapeutics, Ottawa Laboratories, Ottawa, ON K2K 3A2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Davis","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Immunotherapeutics, Ottawa Laboratories, Ottawa, ON K2K 3A2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5538-1363","authenticated-orcid":false,"given":"Michael","family":"McCluskie","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Immunotherapeutics, Ottawa Laboratories, Ottawa, ON K2K 3A2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,5,17]]},"reference":[{"unstructured":"(2016, November 30). WHO Report on the Global Tobacco Epidemic. 2011: Warning about the Dangers of Tobacco. Available online: http:\/\/www.who.int\/tobacco\/global_report\/2011\/en\/.","key":"ref_1"},{"unstructured":"(2016, November 30). Tobacco\u2014Fact Sheet No. 339. Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs339\/en\/.","key":"ref_2"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1360-0443.2004.00540.x","article-title":"Shape of the relapse curve and long-term abstinence among untreated smokers","volume":"99","author":"Hughes","year":"2004","journal-title":"Addiction"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.5993\/AJHB.32.6.10","article-title":"Varenicline versus bupropion SR or placebo for smoking cessation: A pooled analysis","volume":"32","author":"Nides","year":"2008","journal-title":"Am. J. Health Behav."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(08)60871-5","article-title":"Tobacco addiction","volume":"371","author":"Hatsukami","year":"2008","journal-title":"Lancet"},{"key":"ref_6","first-page":"11","article-title":"Therapeutic vaccines for nicotine dependence","volume":"8","author":"Maurer","year":"2006","journal-title":"Curr. Opin. Mol. Ther."},{"doi-asserted-by":"crossref","unstructured":"Pryde, D.C., Jones, L.H., Gervais, D.P., Stead, D.R., Blakemore, D.C., Selby, M.D., Brown, A.D., Coe, J.W., Badland, M., and Beal, D.M. (2013). Selection of a novel anti-nicotine vaccine: Influence of antigen design on antibody function in mice. PLoS ONE, 8.","key":"ref_7","DOI":"10.1371\/journal.pone.0076557"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","article-title":"Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities","volume":"34","author":"Vollmer","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.intimp.2015.02.030","article-title":"Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates","volume":"25","author":"McCluskie","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.intimp.2015.09.012","article-title":"Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates","volume":"29","author":"McCluskie","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.intimp.2013.03.021","article-title":"Enhancing immunogenicity of a 3\u2019aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates","volume":"16","author":"McCluskie","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/clpt.1984.67","article-title":"Daily intake of nicotine during cigarette smoking","volume":"35","author":"Benowitz","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0021-9258(19)77988-5","article-title":"The pH-dependent conformational change of Diphtheria toxin","volume":"263","author":"Dumont","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1021\/bi00341a027","article-title":"Effect of pH on the conformation of Diphtheria toxin and its implication for membrane penetration","volume":"24","author":"Blewitt","year":"1985","journal-title":"Biochemistry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1073\/pnas.91.8.3127","article-title":"Domain swapping: Entangling alliances between proteins","volume":"91","author":"Bennett","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1073\/pnas.1201964109","article-title":"Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197","volume":"109","author":"Malito","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"unstructured":"Hermanson, G.T. (2008). Bioconjugatio Techniques, Elsevier Inc.. [2nd ed.].","key":"ref_17"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.xphs.2016.04.017","article-title":"Production and characterization of chemically inactivated genetically engineered Clostridium difficile toxoids","volume":"105","author":"Vidunas","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1089","DOI":"10.1038\/srep01089","article-title":"Peptide-conjugation induces changes in human IgG1 observed by optimized negative-staining and individual-particle electron tomography","volume":"3","author":"Tong","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/acs.bioconjchem.6b00043","article-title":"Systematic investigation of EDC\/sNHS-mediated bioconjugation reactions for carboxylated peptide substrates","volume":"27","author":"Totaro","year":"2016","journal-title":"Bioconj. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.vaccine.2014.11.026","article-title":"Carrier priming with CRM197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: Biophysical and immunochemical interpretation","volume":"33","author":"Pecetta","year":"2015","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.vaccine.2005.05.041","article-title":"Relationships among physico-chemical and biological tests for a synthetic Hib-TT conjugate vaccine","volume":"25","author":"Cuervo","year":"2007","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1016\/S0264-410X(01)00024-X","article-title":"Effect of physico-chemical modification on the immunogenicity of Haemophilus. influenzae type b oligosaccharide-CRM197 conjugate vaccines","volume":"19","author":"Bolgiano","year":"2001","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterization of glycoconjugate vaccines for prevention of meningococcal diseases","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/5\/2\/11\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:36:08Z","timestamp":1760207768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/5\/2\/11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,17]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6]]}},"alternative-id":["vaccines5020011"],"URL":"https:\/\/doi.org\/10.3390\/vaccines5020011","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2017,5,17]]}}}